Search results
Results from the WOW.Com Content Network
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows. Lindsey Leake. Updated December 20, 2024 at 4:34 PM.
The Truqap combination enters a competitive market of breast cancer treatments, which include AstraZeneca-Daiichi Sankyo's Enhertu and Gilead's Trodelvy. ... US FDA approves AstraZeneca's breast ...
Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.
(Reuters) - AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall ...
Its breast cancer therapy Enhertu is made by its partner Daiichi Sankyo in Japan. ... AstraZeneca has a wide portfolio of in-house ADCs, which includes six wholly owned ADCs in clinic and more in ...
In March 2019, AstraZeneca announced it will pay up to US$6.9 billion to work with Daiichi Sankyo Co Ltd on an experimental treatment for breast cancer. AstraZeneca plans to use some of the proceeds of a US$3.5 billion share issue to fund the deal. The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16%. [70]
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer ...